Market Place
Sourcing Support
Ampersand Completes Acquisition of Nektar’s PEG Business
02 Dec 2024 //
PR NEWSWIRE
Nektar Therapeutics Presents NKTR-422 Preclinical Data at ACR
18 Nov 2024 //
PR NEWSWIRE
Nektar Presents Late-Breaking Phase 2 Results of NKTR-255 at SITC
07 Nov 2024 //
PR NEWSWIRE
Nektar extends cash runway with $90M manufacturing plant sale
05 Nov 2024 //
FIERCE PHARMA
Nektar Reaches Agreement to Sell PEGylation Manufacturing Business
04 Nov 2024 //
PR NEWSWIRE
Nektar Publishes Ph 1B For Rezpegaldesleukin In Skin Diseases
29 Oct 2024 //
PR NEWSWIRE
Nektar Therapeutics Reports Second Quarter 2024 Financial Results
08 Aug 2024 //
PR NEWSWIRE
Nektar`s NKTR-0165 TNFR2 Agonist Preclinical Data At EULAR
12 Jun 2024 //
PR NEWSWIRE
Nektar Therapeutics Reports First Quarter 2024 Financial Results
09 May 2024 //
PR NEWSWIRE
Biolojic: Nektar Options TNFR2 AI-Designed Antibody
24 Apr 2024 //
GLOBENEWSWIRE
Nektar Announces Initiation of Phase 2b Study Evaluating Rezpegaldesleuki
05 Mar 2024 //
PR NEWSWIRE
Nektar Therapeutics Announces $30 Million Private Placement Financing with TCGX
04 Mar 2024 //
PR NEWSWIRE
Nektar Management to Present at the TD Cowen 44th Annual Health Care Conference
27 Feb 2024 //
PR NEWSWIRE
Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2023
26 Feb 2024 //
PR NEWSWIRE
Nektar Management To Present at 42nd Annual J.P. Morgan Healthcare Conference
03 Jan 2024 //
PR NEWSWIRE
Nektar and Collaborators Present Data on NKTR-255 in Presentation
11 Dec 2023 //
PR NEWSWIRE
Nektar Therapeutics Reports Third Quarter 2023 Financial Results
07 Nov 2023 //
PR NEWSWIRE
Nektar to Announce Financial Results for the Third Quarter 2023
31 Oct 2023 //
PR NEWSWIRE
Nektar Presents New Responder Data for Rezpegaldesleukin
13 Oct 2023 //
PR NEWSWIRE
Nektar Announces New Clinical Study Collaboration with Cellular Biomedicine
27 Sep 2023 //
PR NEWSWIRE
Nektar Announces Promising Data from Phase 1b Study of Rezpegaldesleukin
13 Sep 2023 //
PR NEWSWIRE
Nektar Therapeutics Reports Second Quarter 2023 Financial Results
08 Aug 2023 //
PR NEWSWIRE
Nektar CEO slams Lilly’s ‘egregious error,` laments lost time
08 Aug 2023 //
FIERCE BIOTECH
Nektar Therapeutics sues Eli Lilly over autoimmune disease treatment
08 Aug 2023 //
REUTERS
Nektar Announces Promising New and Corrected Rezpegaldesleukin Efficacy Data
07 Aug 2023 //
PR NEWSWIRE
Nektar to Participate in Fireside Chat at Goldman 44th Healthcare Conference
12 Jun 2023 //
PR NEWSWIRE
Nektar Therapeutics Reports First Quarter 2023 Financial Results
09 May 2023 //
PR NEWSWIRE
Lilly hands rights to immunology med back to Nektar
28 Apr 2023 //
FIERCE BIOTECH
Nektar Therapeutics Announces It Will Regain Full Rights to Rezpegaldesleukin
27 Apr 2023 //
PR NEWSWIRE
Nektar Announces Strategic Reprioritization & Cost Restructuring Plan
17 Apr 2023 //
PR NEWSWIRE
Nektar Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results
28 Feb 2023 //
PR NEWSWIRE
Nektar’s latest PhII flop threatens to unravel $400M-plus deal with Eli Lilly
25 Feb 2023 //
ENDPTS
Nektar Therapeutics` autoimmune disease drug fails mid-stage study
24 Feb 2023 //
REUTERS
Nektar pins comeback hopes on Lilly collab and cancer combinator
11 Jan 2023 //
FIERCE BIOTECH
Nektar Announces Poster Presentations at ASH Annual Meeting
12 Dec 2022 //
PRNEWSWIRE
Nektar Therapeutics to Host Investor & Analyst Event on December 12th
05 Dec 2022 //
PRNEWSWIRE
Nektar Presents Preclinical Data PEGylated Interferon Gamma Program, NKTR-288
10 Nov 2022 //
PRNEWSWIRE
Nektar and Collaborators Announce Publication in Blood Advances Data NKTR-255
09 Nov 2022 //
PRNEWSWIRE
Sanofi reveals setback for cancer drug acquired in Synthorx buyout
29 Oct 2022 //
BIOPHARMADIVE
UPDATE: Record scratch—Nektar and PureTech`s merger talks are off
11 Oct 2022 //
FIERCEBIOTECH
PureTech confirms negotiations for a possible Nektar merger
09 Oct 2022 //
PHARMAPHORUM
Nektar`s plans to buy PureTech confirmed
08 Oct 2022 //
FIERCEBIOTECH
Nektar Therapeutics Presents Data for Rezpegaldesleukin (LY3471851)
07 Sep 2022 //
PRNEWSWIRE
Nektar and Collaborators Announce Preclinical Publication of Data for NKTR-255
16 Aug 2022 //
PRNEWSWIRE
Nektar Therapeutics Reports Second Quarter 2022 Financial Results
04 Aug 2022 //
PRNEWSWIRE
Nektar to Announce Financial Results for the Second Quarter 2022 on Thursday
26 Jul 2022 //
PRNEWSWIRE
Nektar Announces Promotion of Jillian B. Thomsen to Senior VP & CFO
01 Jul 2022 //
PRNEWSWIRE
In wake of IL-2 shutdown, Nektar lets go of 500+ staffers as it promises
27 Apr 2022 //
ENDPTS
Nektar Therapeutics Announces Strategic Reorganization Plan & Corporate Outlook
26 Apr 2022 //
PRESS RELEASE
Nektar & Collaborators Present Preclinical Data on NKTR-255, a Novel IL-15
25 Apr 2022 //
PRNEWSWIRE
BMS, Nektar end $3.6B I-O program after 2 more late-stage flops
16 Apr 2022 //
FIERCEBIOTECH
Nektar, BMS drug combination fails in late-stage melanoma trial
15 Mar 2022 //
BIOPHARMADIVE
Nektar Tx Reports Q4 and Year-End 2021 Financial Results
28 Feb 2022 //
PRNEWSWIRE
Exelixis Initiates Phase 1b Trial of XL092 with Immuno-oncology Therapies
15 Dec 2021 //
BUSINESSWIRE
Nektar Presents Clinical Data for NKTR-255 in Hematologic Malignancies
11 Dec 2021 //
PRNEWSWIRE
Nektar Therapeutics Appoints Diana M. Brainard
15 Nov 2021 //
PRNEWSWIRE
Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors
09 Nov 2021 //
PRESS RELEASE
RayzeBio Appoints Mary Tagliaferri to its Board of Directors and more
12 Oct 2021 //
BUSINESSWIRE
Nektar Announces New Clinical Collaboration with Merck KGaA and Pfizer Inc.
21 Sep 2021 //
PRNEWSWIRE
Nektar’ experimental cancer therapy requires “significant derisking” - BofA
10 Sep 2021 //
SEEKINGALPHA
